Making Progress Against the Blood-Brain Barrier
January 31st 2022Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.
Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma
January 24th 2022Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.